Immunotherapy
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients
ORLANDO – All 10 patients responded to anti-BCMA CAR T-cell therapy, including 3 patients who had previously failed BCMA-directed therapy.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
‘Real-world’ data show CAR T therapies are cost effective
ORLANDO – An analysis of Medicare claims data found that treatment with CAR T-cell therapy was associated with fewer hospitalizations and shorter...
Conference Coverage
An off-the-shelf drug to rival CAR T cells: ‘very exciting’
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/...
Conference Coverage
Off-the-shelf cellular therapy shows promise in the lab
ORLANDO – Findings from this preclinical research support moving forward with a phase 1 study of the therapy, as monotherapy or combined with...
Conference Coverage
Bispecific CAR T-cells yield high response rate in relapsed/refractory myeloma
ORLANDO – Duration of response, manageable safety support further investigation of dual-targeted strategy, according to investigator.
Conference Coverage
High complete response rate seen with novel CAR-T for myeloma
ORLANDO – A CAR T product targeting B-cell maturation antigen, one of several in development, was associated with a 100% overall response rate.
Conference Coverage
ASH preview: Key themes include tackling CAR T obstacles, sickle cell advances, VTE
New findings take aim at CAR T-cell therapy-related obstacles and highlight potential new paths forward.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
Conference Coverage
Will TP53-mutated AML respond to immunotherapy?
NATIONAL HARBOR, MD. – Patients with TP53-mutated AML were shown to have increased immune infiltration, but it isn’t clear if they will respond...